Issue: July 2015
July 07, 2015
1 min read
Save

Trial Scorecard: VENTURE-AF

Issue: July 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers assessed the safety of uninterrupted rivaroxaban vs. uninterrupted warfarin in patients undergoing catheter ablation therapy for AF.

Trial Scorecard: VENTURE-AF